CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 420 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Dexmedetomidine 5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03388541
NCT03388541Phase 4Completed

Does LOW Dose DEXmedetomidine After Cardiopulmonary Bypass Separation Decrease the Incidence of DELirium: A Double-blind Randomized Placebo-controlled Study (LOWDEXDEL Study)

Cliniques universitaires Saint-Luc- Université Catholique de Louvain·interventional·Posted Jan 3, 2018·Updated Sep 30, 2020

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine and Placebo for Cardiac Surgical Procedures. Completed, enrolled 420 participants across 1 site.

Detailed Summary

Delirium after cardiac surgery can occur in up to 50% of the patients and has been shown to be significantly associated with increased morbidity and mortality. Advanced age is a significant risk factor of delirium. Numerous studies have shown that sedation with high doses of Dexmedetomidine in the ICU reduces the incidence of postoperative delirium. On the other hand animal studies have shown neuroprotective effects of Dexmedetomidine by means of stimulating alpha2A-adrenoceptors. It is not clear whether the administration of a low dose Dexmedetomidine in cardiac surgery would have any neuroprotective effects by stimulating the alpha 2A-receptors and as such would decrease the incidence of postoperative delirium.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJan 3, 2018
Enrollment StartJan 17, 2018
Primary CompletionAug 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.5 years ago

Interventions

Dexmedetomidinedrug

Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.

Placebodrug

A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.